Further positive results for VAL001
Respiratorius announces that valproate has demonstrated enhanced inhibiting effects on cell growth, so-called antiproliferative effects, in combination with etoposide, which in recent years has been introduced together with standard R-CHOP therapy for DLBCL patients requiring more intense treatment. Based on these results, VAL001 demonstrates its potential as a pretreatment for R-CHOEP as well as R-CHOP therapy.Chemotherapy consisting of a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in combination with immunotherapy targeting CD20 such as rituximab (so-